Business Wire

Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware

16.3.2026 14:00:00 CET | Business Wire | Press release

Share

Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners

Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/

Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device

Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (energization) tests in 2027.

It also highlights Helical Fusion’s role in leading a “Japan-style public–private partnership (PPP)” for fusion commercialization. By bringing together NIFS’s world-class research foundation and infrastructure with Helical Fusion’s private-sector system integration and the manufacturing capabilities of industrial partners, the company is building a tightly coupled build-and-test loop.

In Phase 1, Helical Fusion will assemble a non-planar helical high-temperature superconducting (HTS) magnet and conduct current tests to validate the magnet’s performance as a system under expected operating conditions. In magnetic-confinement fusion, the magnet is a core technology that fundamentally shapes performance, reliability, and economics. As international competition intensifies, Helical Fusion is advancing a development model that connects research excellence with manufacturing execution and hardware integration.

Overview of Demonstration Phases within the Helix Program

1) Helix HARUKA — Phase 1 (Magnet Demonstration)

Purpose: Current-testing of a non-planar helical HTS magnet system.
Location: Dedicated space for the joint research group on the NIFS campus.

2) Helix HARUKA — Phase 2 (Integrated Demonstration)

Purpose: Integrated demonstration of key enabling technologies—including the HTS magnet and the blanket/divertor—together with a key milestone of the program: demonstrating sustained high-temperature plasma operation for durations sufficient to underpin an engineering outlook toward steady-state power-plant operation. This is intended to establish technical confidence for the first power-generating unit, Helix KANATA.
Note: No power generation will be conducted in Phase 2.
Location: Not disclosed.

3) Helix KANATA (First Power-Generating Unit)

Purpose: Achieve “practical power generation,” including net-electric operation, steady-state operation, and maintainability demonstrations.
Location: Not disclosed.

Background

Collaboration with NIFS

NIFS is a leading public research institution driving helical stellarator fusion research, operating the Large Helical Device (LHD), one of the world’s foremost large-scale plasma experimental facilities for the stellarator approach. Through LHD, NIFS has accumulated key operating know-how for long-duration operation, including sustaining plasma for 3,268 seconds (54 minutes 28 seconds), alongside advances in plasma stability control and management of heat and particle loads. NIFS is also recognized for deep expertise in fusion reactor engineering design

Helical Fusion was founded in 2021 as a spin-out leveraging research outcomes from NIFS. Since 2024, Helical Fusion and NIFS have operated under a formal joint research framework, collaborating on key technologies including HTS magnet systems and blanket/divertor systems. By locating Phase 1 at the dedicated joint workspace on the NIFS campus, Helical Fusion will more tightly connect research and hardware buildout—accelerating engineering integration.

This structure is emerging as a leading example of how Japan can commercialize fusion: a national research institution providing deep scientific and engineering knowledge, a startup driving speed and plant-level system integration, and industrial partners contributing manufacturing and execution capability. Helical Fusion believes this public–private model can become a distinctive strength of Japan’s fusion industry.

About Helical Fusion

Helical Fusion is pursuing the commercialization of fusion energy through the Helical Stellarator. Japan’s helical approach has been advanced through decades of R&D across national universities and public research institutions, and is regarded as well-suited to the requirements of commercial power generation. Building on that foundation, Helical Fusion is executing the Helix Program, which targets: (i) completion of standalone demonstrations of two major development elements—HTS magnets and the blanket/divertor—during the 2020s; and (ii) integrated demonstration via Helix HARUKA and the achievement of commercially viable power generation with Helix KANATA during the 2030s.

Reference: https://www.youtube.com/watch?v=XMXTviHZe6w

Company Overview

Company Name: Helical Fusion Co., Ltd.
Head Office: Chuo-ku, Tokyo, Japan
CEO: Takaya Taguchi
Business: Design and development of the Helical Stellarator

View source version on businesswire.com: https://www.businesswire.com/news/home/20260316066384/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 15:00:00 CEST | Press release

A new technical committee will define how publishers can independently confirm AI companies' reports of content use. FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magn

Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 14:02:00 CEST | Press release

Special-Edition Korea-Made Skin Care Collection Launches In 40 Markets, Available While Supplies Last Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 14:00:00 CEST | Press release

Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1 GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subje

Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press release

The installation marks a significant step in the evolution of premium No/Low wines, where preserving aroma and sensory quality has become a defining industry priority. Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking exper

Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press release

Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye